[Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)].
We describe an immunochemotherapy for metastatic melanoma that combines epifocal applications of the contact sensitizer DNCB over cutaneous metastases with systemic DTIC treatment. 4 complete remissions and 3 partial remissions were achieved in 15 patients. 6 of these remissions were seen in the 7 previously untreated patients. The advantages of this therapy which is in particular interesting for dermatologists are tolerable side effects and low costs. This publication is designed to stimulate larger randomized trials in order to answer open questions.
Trcka
J
J
Universitäts-Hautklinik Würzburg.
Kämpgen
E
E
Becker
J C
JC
Schwaaf
A
A
Bröcker
E B
EB
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage*; D004137:Dinitrochlorobenzene / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007509:Irritants / Q000008:administration & dosage*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004137:Dinitrochlorobenzene; D007509:Irritants; D003606:Dacarbazine
Immunchemotherapie des malignen Melanoms. Epifokale Applikation von Dinitrochlorbenzol (DNCB) kombiniert mit systemischer Chemotherapie mit Dacarbacin (DTIC).